Crohn Disease
📧 Sign up to get email alerts when something new happens for Crohn Disease.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Hulio (adalimumab) biosimilar with approvals across multiple inflammatory indications.
-
EMA approval · 2026-08-26EMA Authorised: Skyrizi (risankizumab) — AbbVie Deutschland GmbH & Co. KG
Regulatory authorization for Skyrizi (risankizumab) by AbbVie Deutschland GmbH & Co. KG across multiple inflammatory diseases.
-
EMA approval · 2026-08-24EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) for multiple inflammatory diseases including rheumatoid arthritis and Crohn's disease.
-
EMA approval · 2026-08-18EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.
Amgevita (adalimumab) by Amgen Europe B.V. has been authorised by the EMA for multiple inflammatory diseases including arthritis, psoriatic …
-
EMA approval · 2026-08-18EMA Authorised: Stelara (ustekinumab) — Janssen-Cilag International NV
EU authorises Stelara (ustekinumab) for multiple indications including psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colit…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-08-13Clinical Trial Results: A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease [Phase 2]
Phase 2 trial assessing long-term efficacy, safety, and tolerability of repeated upadacitinib (ABT-494) in Crohn's disease; results posted a…
-
EMA approval · 2026-08-11EMA Authorised: Usgena (ustekinumab) — Stada Arzneimittel AG
Stada Arzneimittel AG authorized to market Usgena (ustekinumab) for Crohn's disease, psoriasis, psoriatic arthritis, and ulcerative colitis …
-
EMA approval · 2026-08-11EMA Authorised: Yesintek (ustekinumab) — Biosimilar Collaborations Ireland Limited
Yesintek (ustekinumab) from Biosimilar Collaborations Ireland Limited has been authorised by the EMA for psoriasis, psoriatic arthritis, and…
-
CLINICAL_TRIALS trial_result · 2026-08-11Clinical Trial Results: Study of ExoFlo for the Treatment of Perianal Fistulas [Phase 1, Phase 2]
Phase 1/2 study evaluating ExoFlo for perianal fistulas in Crohn's disease; trial has been terminated with results posted.
-
EMA approval · 2026-08-06EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) from Fresenius Kabi Deutschland for multiple inflammatory diseases including rheuma…
-
EMA approval · 2026-08-05EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
EMA authorises Humira (adalimumab) for multiple inflammatory diseases across indications, confirming market authorization.
-
EMA withdrawal · 2026-07-31EMA Withdrawn: Qoyvolma (ustekinumab) — Celltrion Healthcare Hungary Kft.
The EMA has withdrawn Qoyvolma (ustekinumab) from the market.
-
EMA approval · 2026-07-30EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
Biosimilar adalimumab (Hulio) has been authorised by EMA for multiple indications including hidradenitis suppurativa, psoriasis, uveitis, rh…
-
CLINICAL_TRIALS trial_result · 2026-07-30Clinical Trial Results: A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease [Phase 3]
Phase 3 clinical trial results evaluating ustekinumab in pediatric patients with moderately to severely active Crohn's disease have been com…
-
EMA withdrawal · 2026-07-28EMA Withdrawn: Inflectra (infliximab) — Pfizer Europe MA EEIG
The EMA has withdrawn Inflectra (infliximab) from the market.
-
EMA approval · 2026-07-17EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EU authorization of Hukyndra (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases including rheumatoid arthritis and inf…
-
EMA approval · 2026-07-15EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG
Rinvoq (upadacitinib) has been authorised by the EMA for multiple inflammatory diseases including rheumatoid arthritis, psoriatic arthritis,…
-
EMA approval · 2026-07-13EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
Authorised status for Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory and autoimmune diseases.
-
EMA approval · 2026-07-13EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) for multiple inflammatory diseases, expanding the portfolio under Fresenius Kabi De…
-
CLINICAL_TRIALS trial_result · 2026-07-07Clinical Trial Results: PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease [Phase 2]
Phase 2 clinical trial results for PDA001 in adults with moderate-to-severe Crohn's disease have been completed and results posted.
-
EMA approval · 2026-07-03EMA Authorised: Pyzchiva (ustekinumab) — Samsung Bioepis NL B.V.
EU authorization of Pyzchiva (ustekinumab) for Crohn's disease, ulcerative colitis, and psoriatic arthritis.
-
EMA approval · 2026-07-01EMA Authorised: Wezenla (ustekinumab) — Amgen Technology (Ireland) UC
Authorised approval of Wezenla (ustekinumab) by EMA for psoriasis, psoriatic arthritis, and Crohn's disease.
-
CLINICAL_TRIALS trial_result · 2026-07-01Clinical Trial Results: A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease [Phase 2, Phase 3]
A clinical trial evaluating oral etrasimod for moderately to severely active Crohn's disease has completed phases 2 and 3 with results poste…
-
EMA approval · 2026-06-25EMA Authorised: Skyrizi (risankizumab) — AbbVie Deutschland GmbH & Co. KG
EU authorisation of Skyrizi (risankizumab) for multiple inflammatory diseases including psoriasis, psoriatic arthritis, ulcerative colitis, …
-
CLINICAL_TRIALS trial_result · 2026-06-23Clinical Trial Results: ENhanced Recovery in CHildren Undergoing Surgery [Phase 3]
Phase 3 trial results for enhanced recovery in children undergoing surgery for inflammatory bowel disease, including Crohn's disease and ulc…